Compare NVRI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVRI | PGEN |
|---|---|---|
| Founded | 1853 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | NVRI | PGEN |
|---|---|---|
| Price | $17.97 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 1.3M | ★ 4.7M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,240,358,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | $3.12 | $478.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.72 | $1.11 |
| 52 Week High | $19.48 | $5.47 |
| Indicator | NVRI | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 38.32 |
| Support Level | $17.86 | $3.49 |
| Resistance Level | $18.62 | $5.10 |
| Average True Range (ATR) | 0.61 | 0.29 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 44.71 | 14.68 |
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.